We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Alexander Drilon, MD
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Charu Aggarwal, MD, MPH
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Intracranial Activity of ROS1 TKIs
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Early Recognition and Diagnosis of Castleman Disease
Sanam Loghavi, MD
Razelle Kurzrock, MD, FACP
Keeping Pace in Lung Cancer - Breaking Barriers: Advances in Treating EGFR Exon 20 Insertions in NSCLC
Heather Wakelee, MD, FASCO
Lyudmila Bazhenova, MD
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education